This report provides comprehensive information on the therapeutic development for Neuroendocrine Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors) and special features on late-stage and discontinued projects.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Table of Contents:
Companies Involved in Therapeutics Development
- Neuroendocrine Tumors Overview
- Therapeutics Development
- Pipeline Products for Neuroendocrine Tumors - Overview
- Pipeline Products for Neuroendocrine Tumors - Comparative Analysis
- Neuroendocrine Tumors - Therapeutics under Development by Companies
- Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes
- Neuroendocrine Tumors Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Neuroendocrine Tumors - Products under Development by Companies
- Neuroendocrine Tumors - Products under Investigation by Universities/Institutes
- Neuroendocrine Tumors - Companies Involved in Therapeutics Development
- Advanced Accelerator Applications S.A.
- Aegis Therapeutics, LLC
- Amgen Inc.
- AVEO Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
- Chiasma, Inc.
- Crinetics Pharmaceuticals, Inc.
- Daiichi Sankyo Company, Limited
- Delcath Systems, Inc.
- DexTech Medical AB
- Eisai Co., Ltd.
- Exelixis, Inc.
- Foresee Pharmaceuticals, LLC
- Hutchison MediPharma Limited
- Intezyne, Inc
- INVENT Pharmaceuticals, Inc.
- Ipsen S.A.
- Jiangsu Hengrui Medicine Co., Ltd.
- Karyopharm Therapeutics, Inc.
- Lexicon Pharmaceuticals, Inc.
- Midatech Pharma Plc
- Millennium Pharmaceuticals, Inc.
- MolMed S.p.A.
- Northwest Biotherapeutics, Inc.
- Novartis AG
- OctreoPharm Sciences GmbH
- OXiGENE, Inc.
- Peptron, Inc.
- Pfizer Inc.
- Pharma Mar, S.A.
- Progenics Pharmaceuticals, Inc.
- Provectus Biopharmaceuticals, Inc.
- Sompharmaceuticals S.A.
- Strongbridge Biopharma plc
- Vascular Biogenics Ltd.
Please find more about Neuroendocrine Tumors - Pipeline Review, H1 2016 at reports.zursh.com
Click on below items to see free updates about the topic covered.
Click on below items to see free resources and reports about the topic covered.